Regenexx Patents: The Regenexx Team has been Granted Two Patents this Past Few Months…
We are proud to report on two new Regenexx Patents. What we do at Regenexx goes beyond treating patients. We also develop new medical technologies in the field of interventional orthopedics. This includes filing patents on our novel devices or biologic treatments. As a result, this past month we were granted two new Regenexx patents by both the US and European patent offices. The first patent granted by the USPTO was for a novel device that combines stem cells with a hydrogel carrier at the patient’s bedside for injection or surgical re-implantation. The European patent is for the use of cultured stem cells for cartilage repair using the same technique as pioneered with Regenexx-C. This utilizes the growth factors from the patient’s own platelets to grow cells in culture and then provides a signal to the cells to become cartilage. Our own internal research has shown that this cartilage signal improves patient outcome. The upshot? We’re proud to not only treat patients, but to develop the next generation of medical technologies!
If you have questions or comments about this blog post, please email us at [email protected]
NOTE: This blog post provides general information to help the reader better understand regenerative medicine, musculoskeletal health, and related subjects. All content provided in this blog, website, or any linked materials, including text, graphics, images, patient profiles, outcomes, and information, are not intended and should not be considered or used as a substitute for medical advice, diagnosis, or treatment. Please always consult with a professional and certified healthcare provider to discuss if a treatment is right for you.